These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

709 related articles for article (PubMed ID: 14697436)

  • 1. Evaluation of salivary gland function after treatment of head-and-neck tumors with intensity-modulated radiotherapy by quantitative pertechnetate scintigraphy.
    Münter MW; Karger CP; Hoffner SG; Hof H; Thilmann C; Rudat V; Nill S; Wannenmacher M; Debus J
    Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):175-84. PubMed ID: 14697436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results.
    Chao KS; Deasy JO; Markman J; Haynie J; Perez CA; Purdy JA; Low DA
    Int J Radiat Oncol Biol Phys; 2001 Mar; 49(4):907-16. PubMed ID: 11240231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose, volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer.
    Eisbruch A; Ten Haken RK; Kim HM; Marsh LH; Ship JA
    Int J Radiat Oncol Biol Phys; 1999 Oct; 45(3):577-87. PubMed ID: 10524409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective investigation and literature review of tolerance dose on salivary glands using quantitative salivary gland scintigraphy in the intensity-modulated radiotherapy era.
    Lee SW; Kang KW; Wu HG
    Head Neck; 2016 Apr; 38 Suppl 1():E1746-55. PubMed ID: 26875880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recovery of Salivary Function: Contralateral Parotid-sparing Intensity-modulated Radiotherapy versus Bilateral Superficial Lobe Parotid-sparing Intensity-modulated Radiotherapy.
    Miah AB; Gulliford SL; Morden J; Newbold KL; Bhide SA; Zaidi SH; Hall E; Harrington KJ; Nutting CM
    Clin Oncol (R Coll Radiol); 2016 Sep; 28(9):e69-e76. PubMed ID: 26994893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence for early and persistent impairment of salivary gland excretion after irradiation of head and neck tumours.
    Liem IH; Olmos RA; Balm AJ; Keus RB; van Tinteren H; Takes RP; Muller SH; Bruce AM; Hoefnagel CA; Hilgers FJ
    Eur J Nucl Med; 1996 Nov; 23(11):1485-90. PubMed ID: 8854847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensity-modulated radiotherapy or volumetric-modulated arc therapy in patients with head and neck cancer: Focus on salivary glands dosimetry.
    Vallard A; Guy JB; Mengue Ndong S; Vial N; Rivoirard R; Auberdiac P; Méry B; Langrand-Escure J; Espenel S; Moncharmont C; Ben Mrad M; Diao P; Goyet D; Magné N
    Head Neck; 2016 Jul; 38(7):1028-34. PubMed ID: 26855006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Scintigraphic assessment of salivary function and excretion response in radiation-induced injury of the major salivary glands.
    Valdés Olmos RA; Keus RB; Takes RP; van Tinteren H; Baris G; Hilgers FJ; Hoefnagel CA; Balm AJ
    Cancer; 1994 Jun; 73(12):2886-93. PubMed ID: 8199984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The utility of SPECT in determining the relationship between radiation dose and salivary gland dysfunction after radiotherapy.
    van Acker F; Flamen P; Lambin P; Maes A; Kutcher GJ; Weltens C; Hermans R; Baetens J; Dupont P; Rijnders A; Maes A; van den Bogaert W; Mortelmans L
    Nucl Med Commun; 2001 Feb; 22(2):225-31. PubMed ID: 11258410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer.
    Eisbruch A; Kim HM; Terrell JE; Marsh LH; Dawson LA; Ship JA
    Int J Radiat Oncol Biol Phys; 2001 Jul; 50(3):695-704. PubMed ID: 11395238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conformal and intensity modulated irradiation of head and neck cancer: the potential for improved target irradiation, salivary gland function, and quality of life.
    Eisbruch A; Dawson LA; Kim HM; Bradford CR; Terrell JE; Chepeha DB; Teknos TN; Anzai Y; Marsh LH; Martel MK; Ten Haken RK; Wolf GT; Ship JA
    Acta Otorhinolaryngol Belg; 1999; 53(3):271-5. PubMed ID: 10635407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A study on the impact of patient-related parameters in the ability to spare parotid glands by intensity-modulated radiotherapy for head and neck squamous cell carcinomas.
    Bandlamudi BP; Sharan K; Yathiraj PH; Singh A; Reddy A; Fernandes DJ; Srinivasa VM
    J Cancer Res Ther; 2018; 14(6):1220-1224. PubMed ID: 30488833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of parotid gland irradiation in the development of severe hyposalivation (xerostomia) after intensity-modulated radiation therapy for head and neck cancer: Temporal patterns, risk factors, and testing the QUANTEC guidelines.
    Owosho AA; Thor M; Oh JH; Riaz N; Tsai CJ; Rosenberg H; Varthis S; Yom SH; Huryn JM; Lee NY; Deasy JO; Estilo CL
    J Craniomaxillofac Surg; 2017 Apr; 45(4):595-600. PubMed ID: 28256385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Scintigraphic evaluation of long-term salivary function after bilateral whole parotid gland irradiation in radiotherapy for head and neck tumour.
    Kaneko M; Shirato H; Nishioka T; Ohmori K; Takinami S; Arimoto T; Kagei K; Miyasaka K; Nakamura M
    Oral Oncol; 1998 Mar; 34(2):140-6. PubMed ID: 9682778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parotid gland mean dose as a xerostomia predictor in low-dose domains.
    Gabryś HS; Buettner F; Sterzing F; Hauswald H; Bangert M
    Acta Oncol; 2017 Sep; 56(9):1197-1203. PubMed ID: 28502238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A model for predicting the dose to the parotid glands based on their relative overlapping with planning target volumes during helical radiotherapy.
    Millunchick CH; Zhen H; Redler G; Liao Y; Turian JV
    J Appl Clin Med Phys; 2018 Mar; 19(2):48-53. PubMed ID: 29105949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Smart (simultaneous modulated accelerated radiation therapy) boost: a new accelerated fractionation schedule for the treatment of head and neck cancer with intensity modulated radiotherapy.
    Butler EB; Teh BS; Grant WH; Uhl BM; Kuppersmith RB; Chiu JK; Donovan DT; Woo SY
    Int J Radiat Oncol Biol Phys; 1999 Aug; 45(1):21-32. PubMed ID: 10477002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Xerostomia, salivary characteristics and gland volumes following intensity-modulated radiotherapy for nasopharyngeal carcinoma: a two-year follow up.
    Sim C; Soong YL; Pang E; Lim C; Walker GD; Manton DJ; Reynolds EC; Wee J
    Aust Dent J; 2018 Jun; 63(2):217-223. PubMed ID: 29569726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The potential for sparing of parotids and escalation of biologically effective dose with intensity-modulated radiation treatments of head and neck cancers: a treatment design study.
    Wu Q; Manning M; Schmidt-Ullrich R; Mohan R
    Int J Radiat Oncol Biol Phys; 2000 Jan; 46(1):195-205. PubMed ID: 10656393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of xerostomia incidence after three-dimensional conformal radiation therapy and contralateral superficial lobe parotid-sparing intensity-modulated radiotherapy for oropharyngeal and hypopharyngeal cancer.
    Kawamoto T; Nihei K; Nakajima Y; Kito S; Sasai K; Karasawa K
    Auris Nasus Larynx; 2018 Oct; 45(5):1073-1079. PubMed ID: 29397249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.